{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:46Z","timestamp":1793923966614,"version":"4.8.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40257-026-01013-6","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:30:25Z","timestamp":1773131425000},"page":"277-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of Systemic Treatments for Atopic Dermatitis in the Head-and-Neck-Area: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1161-1985","authenticated-orcid":false,"given":"Elizabeth Munkebjerg","family":"Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8098-6700","authenticated-orcid":false,"given":"Kirstine","family":"Vester-Glowinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-6081","authenticated-orcid":false,"given":"Mette","family":"Gyldenl\u00f8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"1013_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340. https:\/\/doi.org\/10.1038\/s41573-021-00266-6.","journal-title":"Nat Rev Drug Discov"},{"key":"1013_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(15)00149-X.","journal-title":"Lancet"},{"key":"1013_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/DER.0000000000000034","volume":"25","author":"JI Silverberg","year":"2014","unstructured":"Silverberg JI, Simpson EL. Associations of childhood eczema severity. Dermatitis. 2014;25:107\u201314. https:\/\/doi.org\/10.1097\/DER.0000000000000034.","journal-title":"Dermatitis"},{"key":"1013_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284\u201393. https:\/\/doi.org\/10.1111\/all.13401.","journal-title":"Allergy"},{"key":"1013_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/all.12270","volume":"69","author":"C Flohr","year":"2014","unstructured":"Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69:3\u201316. https:\/\/doi.org\/10.1111\/all.12270.","journal-title":"Allergy"},{"key":"1013_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/1346-8138.15664","volume":"48","author":"T Nakahara","year":"2021","unstructured":"Nakahara T, Kido\u2010Nakahara M, Tsuji G, Furue M. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol. 2021;48:130\u20139. https:\/\/doi.org\/10.1111\/1346-8138.15664.","journal-title":"J Dermatol"},{"key":"1013_CR7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384:1136\u201343. https:\/\/doi.org\/10.1056\/NEJMra2023911.","journal-title":"N Engl J Med"},{"key":"1013_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"A-S Halling","year":"2021","unstructured":"Halling A-S, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84:139\u201347. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.051.","journal-title":"J Am Acad Dermatol"},{"key":"1013_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104\u2009weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37:1046\u201355. https:\/\/doi.org\/10.1111\/jdv.18849.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1013_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/jdv.17351","volume":"35","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate\u2010to\u2010severe atopic dermatitis: a systematic literature review and network meta\u2010analysis. J Eur Acad Dermatol Venereol. 2021;35:1797\u2013810. https:\/\/doi.org\/10.1111\/jdv.17351.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1013_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0796","volume":"156","author":"AM Drucker","year":"2020","unstructured":"Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis. JAMA Dermatol. 2020;156:659. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0796.","journal-title":"JAMA Dermatol"},{"key":"1013_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0455","volume":"158","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for atopic dermatitis. JAMA Dermatol. 2022;158:523. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0455.","journal-title":"JAMA Dermatol"},{"key":"1013_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80:390\u2013401. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.035.","journal-title":"J Am Acad Dermatol"},{"key":"1013_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaad.2019.06.018","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol. 2019;81:943\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.018.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1013_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.198","volume":"83","author":"P Lio","year":"2020","unstructured":"Lio P, Cardillo T, Delozier A, Gamalo M, Ball SG, Lilly E, et al. 15054 impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2. J Am Acad Dermatol. 2020;83(6):AB28. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.198.","journal-title":"J Am Acad Dermatol"},{"key":"1013_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.23736\/S0392-0488.17.05892-8","volume":"153","author":"P Calzavara Pinton","year":"2018","unstructured":"Calzavara Pinton P, Cristaudo A, Foti C, Canonica GW, Balato N, Costanzo A, et al. Diagnosis and management of moderate to severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA). G Ital Dermatol Venereol. 2018;153:133\u201345. https:\/\/doi.org\/10.23736\/S0392-0488.17.05892-8.","journal-title":"G Ital Dermatol Venereol"},{"key":"1013_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1013_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1013_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods"},{"key":"1013_CR20","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0538","author":"T Hagino","year":"2025","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness of tralokinumab for different anatomical sites and clinical signs in atopic dermatitis: a 36-week real-world study. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2024.0538. (Epub ahead of print).","journal-title":"Dermatitis"},{"key":"1013_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13555-025-01373-7","volume":"15","author":"S Weidinger","year":"2025","unstructured":"Weidinger S, Schadeck T, Jacobs F, Weyergraf A, Mortazawi D, Hagemann T, et al. Early achievement of high treatment targets in moderate-to-severe atopic dermatitis with upadacitinib: real-world evidence from the observational UP-TAINED study. Dermatol Ther (Heidelb). 2025;15:919\u201331. https:\/\/doi.org\/10.1007\/s13555-025-01373-7.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1013_CR22","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1111\/ijd.17278","volume":"63","author":"G Perego","year":"2024","unstructured":"Perego G, Aromolo IF, Barei F, Valtellini L, Marzano AV, Ferrucci S. Effectiveness of dupilumab in atopic dermatitis on the head and neck: a single-center study on 553 patients. Int J Dermatol. 2024;63:e178\u20139. https:\/\/doi.org\/10.1111\/ijd.17278.","journal-title":"Int J Dermatol"},{"key":"1013_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13555-024-01158-4","volume":"14","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, de Bruin-Weller M, Hong HC-H, Staumont-Sall\u00e9 D, Blauvelt A, Eyerich K, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14:1145\u201360. https:\/\/doi.org\/10.1007\/s13555-024-01158-4.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1013_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s13555-022-00694-1","volume":"12","author":"A Alexis","year":"2022","unstructured":"Alexis A, de Bruin-Weller M, Weidinger S, Soong W, Barbarot S, Ionita I, et al. Rapidity of improvement in signs\/symptoms of moderate-to-severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study. Dermatol Ther (Heidelb). 2022;12:771\u201385. https:\/\/doi.org\/10.1007\/s13555-022-00694-1.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1013_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real\u2010world practice in Japan. J Dermatol. 2023;50:869\u201379. https:\/\/doi.org\/10.1111\/1346-8138.16763.","journal-title":"J Dermatol"},{"key":"1013_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1684\/ejd.2022.4280","volume":"32","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Lio P, Kleyn E, Bissonnette R, Jose Rueda M, Casillas M, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five phase III clinical trials. Eur J Dermatol. 2022;32:522\u20139. https:\/\/doi.org\/10.1684\/ejd.2022.4280.","journal-title":"Eur J Dermatol"},{"key":"1013_CR27","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.2147\/CCID.S439053","volume":"16","author":"T Hagino","year":"2023","unstructured":"Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N. Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:3201\u201312. https:\/\/doi.org\/10.2147\/CCID.S439053.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1013_CR28","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/1346-8138.16950","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Yoshida M, Hamada R, Fujimoto E, Saeki H, Kanda N. Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate-to-severe atopic dermatitis. J Dermatol. 2023;50:1576\u201384. https:\/\/doi.org\/10.1111\/1346-8138.16950.","journal-title":"J Dermatol"},{"key":"1013_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2212095","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023. https:\/\/doi.org\/10.1080\/09546634.2023.2212095.","journal-title":"J Dermatolog Treat"},{"key":"1013_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2276043","author":"T Hagino","year":"2023","unstructured":"Hagino T, Yoshida M, Hamada R, Saeki H, Fujimoto E, Kanda N. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatolog Treat. 2023. https:\/\/doi.org\/10.1080\/09546634.2023.2276043.","journal-title":"J Dermatolog Treat"},{"key":"1013_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000542275","volume":"241","author":"JP Thyssen","year":"2025","unstructured":"Thyssen JP, Rosmarin D, Costanzo A, Warren R, Chu C-Y, Chovatiya R, et al. Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: analysis from the heads up study. Dermatology. 2025;241:10\u20138. https:\/\/doi.org\/10.1159\/000542275.","journal-title":"Dermatology"},{"key":"1013_CR32","doi-asserted-by":"publisher","DOI":"10.1159\/000545227","author":"N Gori","year":"2025","unstructured":"Gori N, Galluzzo M, Chiricozzi A, Grieco T, Chello C, Russo F, et al. Evaluation of upadacitinib efficacy in the treatment of atopic dermatitis of sensitive areas. Dermatology Basel. 2025. https:\/\/doi.org\/10.1159\/000545227.","journal-title":"Dermatology Basel"},{"key":"1013_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.932","volume":"89","author":"D Marcoux","year":"2023","unstructured":"Marcoux D, Ramien M, Antila M, Rosario Filho NA, Lee LW, Rubin C, et al. 43740 the effect of systemic treatment on different anatomical regions in pediatric patients with atopic dermatitis: real-world data from PEDISTAD. J Am Acad Dermatol. 2023;89:AB233. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.932.","journal-title":"J Am Acad Dermatol"},{"key":"1013_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/1346-8138.16039","volume":"48","author":"M Matsutani","year":"2021","unstructured":"Matsutani M, Imai Y, Inoue Y, Nakatani-Kusakabe M, Natsuaki M, Yamanishi K, et al. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice. J Dermatol. 2021;48:1564\u20138. https:\/\/doi.org\/10.1111\/1346-8138.16039.","journal-title":"J Dermatol"},{"key":"1013_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/central\/CN-01620298\/full","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Simpson E, Bieber T, Kawashima M, Rosmarin D, Shumel B, et al. Dupilumab improves atopic dermatitis equally well in all anatomical regions: data from the LIBERTY phase III clinical trials. B J Dermatol. 2018;179:31. https:\/\/doi.org\/10.1002\/central\/CN-01620298\/full.","journal-title":"B J Dermatol."},{"key":"1013_CR36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/jdv.18109","volume":"36","author":"C Gu","year":"2022","unstructured":"Gu C, Wu Y, Luo Y, Wang S, Yin H, Gao Y, et al. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study. J Eur Acad Dermatol Venereol. 2022;36:1064\u201373. https:\/\/doi.org\/10.1111\/jdv.18109.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1013_CR37","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s13555-023-00960-w","volume":"13","author":"EC Siegfried","year":"2023","unstructured":"Siegfried EC, Simpson EL, Cork MJ, Arkwright PD, Wine Lee L, Chen Z, et al. Dupilumab treatment leads to rapid and consistent improvement of atopic dermatitis in all anatomical regions in patients aged 6 months to 5 years. Dermatol Ther (Heidelb). 2023;13:1987\u20132000. https:\/\/doi.org\/10.1007\/s13555-023-00960-w.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1013_CR38","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s13555-021-00568-y","volume":"11","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, et al. Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatol Ther (Heidelb). 2021;11:1643\u201356. https:\/\/doi.org\/10.1007\/s13555-021-00568-y.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1013_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1089\/derm.2024.0146","volume":"35","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Borrelli R, Macagno N, Gelato F, Baima E, Richiardi I, et al. Therapeutic modulation of dupilumab in patients with severe atopic dermatitis\u00ae: clinical effectiveness in real life. Dermatitis. 2024;35:625\u201335. https:\/\/doi.org\/10.1089\/derm.2024.0146.","journal-title":"Dermatitis"},{"key":"1013_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s13555-021-00638-1","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, de Bruin-Weller M, Simpson EL, Chen Z, Zhang A, Shumel B. Dupilumab with topical corticosteroids provides rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across anatomic regions over 52 weeks. Dermatol Ther (Heidelb). 2022;12:223\u201331. https:\/\/doi.org\/10.1007\/s13555-021-00638-1.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1013_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40257-025-00931-1","volume":"26","author":"R Chovatiya","year":"2025","unstructured":"Chovatiya R, Ribero S, Wollenberg A, Park CO, Silvestre JF, Hong HC-H, et al. Long-term disease control and minimal disease activity of head and neck atopic dermatitis in patients treated with tralokinumab up to 4 years. Am J Clin Dermatol. 2025;26:587\u2013601. https:\/\/doi.org\/10.1007\/s40257-025-00931-1.","journal-title":"Am J Clin Dermatol"},{"key":"1013_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(20)30732-7.","journal-title":"Lancet"},{"key":"1013_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/JAMADERMATOL.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.1406.","journal-title":"JAMA Dermatol"},{"key":"1013_CR44","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397:2169\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"key":"1013_CR45","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"key":"1013_CR46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/BJD.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242\u201355. https:\/\/doi.org\/10.1111\/BJD.18898.","journal-title":"Br J Dermatol"},{"key":"1013_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/J.JAAD.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85:62\u201370. https:\/\/doi.org\/10.1016\/J.JAAD.2021.02.028.","journal-title":"J Am Acad Dermatol"},{"key":"1013_CR48","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/JAMADERMATOL.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:1333\u201343. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.3260.","journal-title":"JAMA Dermatol"},{"key":"1013_CR49","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s13555-022-00778-y","volume":"12","author":"J Cather","year":"2022","unstructured":"Cather J, Young M, DiRuggiero DC, Tofte S, Williams L, Gonzalez T. A review of phase 3 trials of dupilumab for the treatment of atopic dermatitis in adults, adolescents, and children aged 6 and up. Dermatol Ther (Heidelb). 2022;12:2013\u201338. https:\/\/doi.org\/10.1007\/s13555-022-00778-y.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1013_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15:2839. https:\/\/doi.org\/10.1038\/s41467-024-46540-0.","journal-title":"Nat Commun"},{"key":"1013_CR51","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","volume":"155","author":"A Soria","year":"2019","unstructured":"Soria A, Du-Thanh A, Seneschal J, Jachiet M, Staumont-Sall\u00e9 D, Barbarot S. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155:1312\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2613.","journal-title":"JAMA Dermatol"},{"key":"1013_CR52","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol. 2024;160:936\u201344. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2192.","journal-title":"JAMA Dermatol"},{"key":"1013_CR53","doi-asserted-by":"publisher","DOI":"10.1177\/17103568251363249","author":"G Avallone","year":"2025","unstructured":"Avallone G, Valtellini L, Tavoletti G, Mastorino L, Maurelli M, Di Brizzi EV, et al. Effectiveness of tralokinumab for moderate-to-severe atopic dermatitis involving the head-and-neck area: a multicenter retrospective cohort study. Dermatitis. 2025. https:\/\/doi.org\/10.1177\/17103568251363249. (Epub ahead of print).","journal-title":"Dermatitis"},{"key":"1013_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.08.085","author":"T-Y Wang","year":"2025","unstructured":"Wang T-Y, Yang Z-H, Tu Y, Li W-F, Hua P-Y, Yao Q-Y, et al. Efficacy of abrocitinib in patients with moderate-to-severe head and neck dermatitis. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.085. (Epub ahead of print).","journal-title":"J Am Acad Dermatol"},{"key":"1013_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaad.2008.07.058","volume":"60","author":"K Darabi","year":"2009","unstructured":"Darabi K, Hostetler SG, Bechtel MA, Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60:125\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2008.07.058.","journal-title":"J Am Acad Dermatol"},{"key":"1013_CR56","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jid.2024.01.001","volume":"144","author":"RL Gallo","year":"2024","unstructured":"Gallo RL, Horswill AR. Staphylococcus aureus: the bug behind the itch in atopic dermatitis. J Invest Dermatol. 2024;144:950\u20133. https:\/\/doi.org\/10.1016\/j.jid.2024.01.001.","journal-title":"J Invest Dermatol"},{"key":"1013_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.70026","author":"A Watanabe","year":"2025","unstructured":"Watanabe A, Kamata M, Okada Y, Suzuki S, Chijiwa C, Tomura Y, et al. Clinical outcomes of tralokinumab and lebrikizumab in japanese atopic dermatitis patients with persistent head and neck dermatitis after long-term treatment with dupilumab: a single-center retrospective study. J Dermatol. 2025. https:\/\/doi.org\/10.1111\/1346-8138.70026. (Epub ahead of print).","journal-title":"J Dermatol"},{"key":"1013_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-031-54513-9_19","volume":"1447","author":"K Lovell","year":"2024","unstructured":"Lovell K, Patel N, Rao S, Strowd LC. The future of atopic dermatitis treatment. Adv Exp Med Biol. 2024;1447:227\u201344. https:\/\/doi.org\/10.1007\/978-3-031-54513-9_19.","journal-title":"Adv Exp Med Biol"},{"key":"1013_CR59","first-page":"804","volume":"18","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, Rendon M, Silverberg JI, Pariser DM, Lockshin B, Griffiths CEM, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J Drugs Dermatol. 2019;18:804\u201313.","journal-title":"J Drugs Dermatol"},{"key":"1013_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00985-1","author":"T Mayo","year":"2025","unstructured":"Mayo T, Silverberg JI, Armstrong A, Guttman-Yassky E, Blauvelt A, Esdaile B, et al. Efficacy and safety of tralokinumab across racial subgroups in adults with moderate-to-severe atopic dermatitis: post hoc analysis of phase III trials. Am J Clin Dermatol. 2025. https:\/\/doi.org\/10.1007\/s40257-025-00985-1.","journal-title":"Am J Clin Dermatol"},{"key":"1013_CR61","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40257-025-00970-8","volume":"26","author":"A Alexis","year":"2025","unstructured":"Alexis A, Moiin A, Waibel J, Wallace P, Cohen D, Laquer V, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: results from the phase iiib, open-label Admirable Study. Am J Clin Dermatol. 2025;26:803\u201317. https:\/\/doi.org\/10.1007\/s40257-025-00970-8.","journal-title":"Am J Clin Dermatol"},{"key":"1013_CR62","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40257-023-00797-1","volume":"24","author":"VL Quan","year":"2023","unstructured":"Quan VL, Erickson T, Daftary K, Chovatiya R. Atopic dermatitis across shades of skin. Am J Clin Dermatol. 2023;24:731\u201351. https:\/\/doi.org\/10.1007\/s40257-023-00797-1.","journal-title":"Am J Clin Dermatol"},{"key":"1013_CR63","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.anai.2025.06.020","volume":"135","author":"K Gallagher","year":"2025","unstructured":"Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Ann Allergy Asthma Immunol. 2025;135:498-510.e10. https:\/\/doi.org\/10.1016\/j.anai.2025.06.020.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1013_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01609-6","author":"A Reich","year":"2025","unstructured":"Reich A, Blauvelt A, Weidinger S, Shi VY, Katoh N, Lynde C, et al. A post hoc analysis of atopic dermatitis of the head and neck and other body regions from the amlitelimab STREAM-AD phase 2b study. Dermatol Ther (Heidelb). 2025. https:\/\/doi.org\/10.1007\/s13555-025-01609-6. (Epub ahead of print).","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1013_CR65","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00403-024-03426-x","volume":"316","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Esfandiari E, Mano H, Arai T, Irvine AD, Cork MJ, et al. Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab. Arch Dermatol Res. 2024;316:747. https:\/\/doi.org\/10.1007\/s00403-024-03426-x.","journal-title":"Arch Dermatol Res"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01013-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01013-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01013-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T11:19:51Z","timestamp":1774696791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01013-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01013-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elizabeth Munkebjerg Stevens: None. Kirstine Vester-Glowinski: None. Lone Skov: Outside the submitted work: research funding from Bristol-Myers Squibb, Janssen Pharmaceuticals, Almirall, Sanofi, the LEO Foundation, and the Kgl. Hofbundtmager Aage Bang Foundation: honoraria as consultant and\/or speaker for AbbVie, Eli Lilly, Novartis, Pfizer, LEO Pharma, Janssen, UCB, Almirall, Galderma, Stada, Bristol Myers Squibb, Takeda, and Sanofi. Mette Gyldenl\u00f8ve: Outside the submitted work: honoraria as consultant and\/or speaker for Galderma Nordic AB and Glenmark Therapeutics. Nikolai Loft: Outside the submitted work: paid speaker for Eli Lilly, Janssen Cilag, Galderma, and Sandoz. Research funding from the LEO Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data that support the findings of this article are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approvals"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors made substantial contributions to the work and approved the final version of the manuscript. Stevens and Loft had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Loft and Gyldenl\u00f8ve. Acquisition, analysis, and interpretation of data: All authors. Drafting of the manuscript: Stevens, Loft, and Vester-Glowinski. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Loft. Administrative, technical, or material support: None.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}